TheraRadar
← Back
Data updated: Mar 29, 2026

BRACCO

CardiovascularOncologyMetabolic
Specialty

BRACCO is a specialty pharmaceutical company focused on Cardiovascular, Oncology, Metabolic. Key products include LUMASON.

1954
Since
67
Drugs
-
Trials
23
Approved (2yr)

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 50%
0 drugs Phase 3: 2
Oncology 38%
0 drugs Phase 2: 3
Metabolic 6%
0 drugs Phase 1: 1
Respiratory 6%
0 drugs Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...